Transforming pharma structure again is necessary because the COVID-19 pandemic has significantly altered the way doctors engage with their patients, and in turn, in the way that pharma companies approach doctors. The growth in remote healthcare in the past few months coupled with the fact that normalcy is unlikely to be restored anytime soon will […]
